NuVasive Inc
F:NK8
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NK8 stock under the Base Case scenario is 40.28 EUR. Compared to the current market price of 36.8 EUR, NuVasive Inc is Undervalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
NuVasive Inc
Run backtest to discover the historical profit from buying and selling NK8 based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
NuVasive Inc
Balance Sheet Decomposition
NuVasive Inc
Current Assets | 728.3m |
Cash & Short-Term Investments | 80.7m |
Receivables | 267.1m |
Other Current Assets | 380.4m |
Non-Current Assets | 1.4B |
PP&E | 452.6m |
Intangibles | 808.3m |
Other Non-Current Assets | 100.4m |
Current Liabilities | 582.6m |
Accounts Payable | 118.8m |
Accrued Liabilities | 60.7m |
Short-Term Debt | 350m |
Other Current Liabilities | 53.1m |
Non-Current Liabilities | 614.4m |
Long-Term Debt | 446.4m |
Other Non-Current Liabilities | 168m |
Earnings Waterfall
NuVasive Inc
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-347.5m
USD
|
Gross Profit
|
878.7m
USD
|
Operating Expenses
|
-796.2m
USD
|
Operating Income
|
82.6m
USD
|
Other Expenses
|
-54.1m
USD
|
Net Income
|
28.5m
USD
|
Free Cash Flow Analysis
NuVasive Inc
USD | |
Free Cash Flow | USD |
NuVasive reported a 2.4% increase in net sales to $317.8 million in the second quarter of 2023. U.S. Cervical business continued to flourish with over 20% growth, albeit against the backdrop of a 9.3% drop in surgical support sales, with non-GAAP gross margin dipping slightly to 71.8%. Despite a competitive market due to merger activities, they maintained solid performance, especially in the U.S. and international core spine segments. Free cash flow declined to $3 million from the previous year's $26 million, attributed to reduced operating cash flow. The earnings outlook remains steady, predicting 6% to 8% growth in net sales for fiscal year 2023, assuming constant currency rates.
What is Earnings Call?
NK8 Profitability Score
Profitability Due Diligence
NuVasive Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
NuVasive Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
NK8 Solvency Score
Solvency Due Diligence
NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NK8 Price Targets Summary
NuVasive Inc
According to Wall Street analysts, the average 1-year price target for NK8 is 74.07 EUR .
Shareholder Yield
Current shareholder yield for NK8 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
NK8 Price
NuVasive Inc
Average Annual Return | -5.54% |
Standard Deviation of Annual Returns | 26.33% |
Max Drawdown | -64% |
Market Capitalization | 1.9B EUR |
Shares Outstanding | 52 449 200 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 2,900 full-time employees. The company went IPO on 2004-05-13. The firm offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for spine and specialized orthopedic procedures. In addition, it also designs and sells expandable growing rod implant systems for the treatment of early-onset scoliosis, which can be non-invasively lengthened implantation with precise, incremental adjustments via an external remote controller using magnetic technology called MAGnetic External Control (MAGEC).
Contact
IPO
Employees
Officers
The intrinsic value of one NK8 stock under the Base Case scenario is 40.28 EUR.
Compared to the current market price of 36.8 EUR, NuVasive Inc is Undervalued by 9%.